Affiliation:
1. Mediprobe Research Inc. London Ontario Canada
2. Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada
3. School of Pharmacy BRAC University Dhaka Bangladesh
Abstract
AbstractBackgroundOral finasteride and topical minoxidil formulations are the only FDA‐approved drug therapies for androgenetic alopecia (AGA). Research into dutasteride, topical finasteride, and nontopical minoxidil (low‐dose oral and sublingual) formulations in the treatment of AGA has spiked within recent years. Early findings show that these alternative drug therapies may have similar to improved efficacy and safety profiles relative to the conventional treatment options.AimsConducting a bibliometric analysis, compare trends in publications on these alternative drug therapies, identify key contributors, evaluate major findings from top‐cited articles, and elucidate gaps in evidence.MethodsA search was conducted on the Web of Science database for publications on the use of alternative drug therapies in the treatment of AGA. A total of 95 publications, published between January 2003—March 2024, and their citation metadata were included in the analysis.ResultsDutasteride showed the greatest (n = 37) and longest (20+ years) history of publications, as well as the highest cumulative citations (n = 914); however, nontopical minoxidil showed a burst in research activity within the last 5 years (n = 33 publications since 2019). A relatively low number of randomized control trials (n = 3) for nontopical minoxidil suggests a need for higher‐quality evidence.ConclusionsOur analysis reveals major trends, contributors, and gaps in evidence for alternative drug therapies for AGA, which can help inform researchers on their future projects in this growing field of study. There is enthusiasm for exploring off‐label formulations: nontopical forms of minoxidil (oral and sublingual), topical finasteride, and mesotherapy.